Extended Data Fig. 3: The substitution A222V in the spike protein has no substantial effect on antigenic properties or replication of pseudotyped lentiviruses.

a, Binding of a serial dilution of NIBSC convalescent plasma to immobilized SARSCoV-2 2P S (blue) or SARS-CoV-2 2P A222V D614G S (red). b, c, Binding of serially diluted concentrations of the human neutralizing antibodies S2E12 (b) and S309 (c) to immobilized SARSCoV-2 2P S (blue) or SARS-CoV-2 2P A222V D614G S (red). d, Binding of serially diluted concentrations of the human neutralizing antibody 4A8 to immobilized SARS-CoV-2 2P S (blue) or SARS-CoV-2 2P A222V D614G S (red). n = 2 experiments performed with independent protein preparations (each in duplicate). Each data point consists of a technical duplicate of each antibody or plasma dilution; error bars, s.d. The experiment shown is representative of two independent experiments. e, Titres of lentiviral particles carrying luciferase in the viral genome. Horizontal line, mean. f, Titres of lentiviral particles carrying the fluorescent protein ZsGreen in the viral genome. Horizontal line, mean. In e, f, titres with the A222V mutation are on average higher by a factor of 1.3. g, Titres of lentiviral particles carrying luciferase in the viral genome normalized by the p24 concentration (pg ml⁻¹) of each viral supernatant. After p24 normalization, the difference in titre shrinks from 1.28- to 1.14-fold, increasing the P value to 0.16. h, Titres of lentiviral particles carrying ZsGreen in the viral genome normalized by the p24 concentration (pg ml⁻¹) of each viral supernatant. P values calculated using two-sided t-test.